Calidi Biotherapeutics, Inc. (CLDI) intrinsic value & 10-year financials
Calidi Biotherapeutics, Inc. (CLDI) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.84
- Market cap
- $3.6K
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 744.0%
- Free cash flow (FY2025)
- —
CLDI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$19.9M | -$5.95 | — | — | 1368.5% |
| FY2024 | — | -$22.1M | -$2.97 | — | — | 689.2% |
| FY2023 | — | -$29.2M | $1.73 | — | — | 1660.8% |
| FY2022 | $45.0K | $3.5M | $1.50 | — | -10376.7% | -742.5% |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Calidi Biotherapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Calidi Biotherapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just 7.4% ROIC.
Calidi Biotherapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Calidi Biotherapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.